Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis

Sponsor
AbbVie (prior sponsor, Abbott)
Study ID
NCT01265823
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Adalimumab — BIOLOGICAL
    Adalimumab was administered as follows: 80 mg at baseline, followed by 40 mg every other week (eow; starting at Week 1 until Week 15). The study drug was self-administered via subcutaneous (sc) injection.

Study Details

W11-050 is a Mexican open label multicenter study that has been designed to further assess the safety and efficacy of adalimumab in the treatment of patients with active plaque psoriasis who have failed prior conventional systemic psoriasis treatment or who are candidates for systemic therapy.

Key Dates

Start date
Oct 31, 2010
Status verified
Feb 2013
Primary completion
Feb 29, 2012
Completion
Feb 29, 2012

Study Design

Enrollment
150 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Adalimumab

Primary Outcome Measure

Percentage of Participants With Psoriasis Area and Severity Index (PASI)-75 Response at Week 4 [ Time Frame: Week 4 ]

Related Studies